Sebia, Inserm Partner to Develop, Commercialize Hemoglobin Disease Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) – French electrophoresis firm Sebia today announced a deal with the French National Institute of Health and Medical Research, or Inserm, to develop and commercialize a test to measure free alpha globin chains in beta-thalassaemic patients.

The deal, which also involved Inserm's technology transfer firm, Inserm Transfert, calls for Sebia to support Inserm's development of the test. Sebia will have the right to acquire exclusive rights to develop the test on an industrial scale and to market it globally.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.